Impact BioMedical Inc.
Health Care · Biotechnology
Structural: microcap biopharma with four early-stage platforms spanning antivirals, antimicrobials, and consumer wellness - all pre-revenue or minimal revenue.
merger with Dr. Ashley's (July 2026 target) could inject commercial revenue and brand-name consumer distribution; 3F and Equivir platforms address persistent unmet need in broad-spectrum antimicrobials.
going-concern qualification, heavy cash burn, no meaningful product revenue, sub-$60M float with thin liquidity - execution and dilution risk are acute.
No major news in the last 7 days for IBO - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.